IRADIMED CORP (IRMD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. IRADIMED CORPORATION develops, manufactures, and distributes MRI-compatible medical devices, including IV infusion pumps, patient vital signs monitoring systems, and ferromagnetic detection systems. The company operates as a single reportable segment serving hospitals and acute care facilities primarily in the United States and internationally.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $21.20 million | $18.33 million | $61.12 million | $53.85 million |
| Gross Profit | $16.49 million | $14.19 million | $47.29 million | $41.59 million |
| Gross Margin | 77.8% | 77.4% | 77.4% | 77.2% |
| Net Income | $5.58 million | $5.05 million | $16.04 million | $14.09 million |
| Diluted EPS | $0.43 | $0.40 | $1.25 | $1.10 |
| Cash & Equivalents | $56.53 million (as of Sept 30, 2025) | |||
| Working Capital | $72.12 million (as of Sept 30, 2025) | |||
| Operating Cash Flow (9M) | $19.02 million |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 16% year-over-year, driven by higher sales of IV infusion pumps, disposables, and patient vital signs monitoring systems. U.S. revenue grew 19% to $18.1 million, while international revenue remained flat at $3.1 million.
- Expense Increases: Operating expenses rose due to higher sales commissions, payroll, and legal/professional fees. Sales and marketing expenses increased 21% in Q3, and General and Administrative (G&A) expenses increased 10%.
- Capital Expenditures: Investing cash outflows increased significantly to $8.0 million for the nine months ended Sept 30, 2025 (vs. $5.8 million in 2024), primarily due to the completion of a new corporate office and manufacturing facility in Orlando, Florida.
- Dividends: The company declared a quarterly cash dividend of $0.17 per share on October 30, 2025, payable November 25, 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects higher revenue for the remainder of fiscal year 2025 compared to the same period in 2024, driven by continued demand for medical devices and disposables. Operating expenses are also expected to be higher due to sales, marketing, and regulatory costs.
- New Product Launch: The FDA granted 510(k) clearance for the next-generation MRidium 3870 IV infusion pump system in May 2025. A strategic rollout to select facilities is planned for Q4 2025, with full commercial distribution expected in 2026.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025. The company does not expect a material change to its annual effective tax rate.
- Risks: Key risks include reliance on a limited number of products, potential delays in regulatory approvals (FDA), supply chain disruptions for sole-sourced components, and the impact of global trade policies and tariffs.
Investor Verification Checklist
- Verify the commercial adoption rate and revenue contribution of the newly cleared MRidium 3870 infusion pump in Q4 2025 and 2026.
- Monitor the impact of the new Orlando facility on future depreciation expenses and operating leverage.
- Assess the sustainability of the 77-78% gross margin given potential inflationary pressures on raw materials and logistics.
- Review the company's strategy to mitigate international revenue stagnation and exposure to global trade tariffs.
- Confirm the timeline for the full commercial distribution of the MRidium 3870 system as projected by management.